Research and Markets: Global Acute Myeloid Leukemia Epidemiology and Patient Flow Analysis 2015

<0> Research and Markets: Global Acute Myeloid Leukemia Epidemiology and Patient Flow Analysis 2015 </0>

<0> Research and MarketsLaura Wood, Senior ManagerFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

The report provides insights into Acute Myeloid Leukemia epidemiology, Acute Myeloid Leukemia diagnosed patients, and Acute Myeloid Leukemia treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Acute Myeloid Leukemia derived from epidemiological analysis, percentage of patients diagnosed with Acute Myeloid Leukemia, and percentage of patients treated with Acute Myeloid Leukemia therapy.

The study helps executives estimate Acute Myeloid Leukemia market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Acute Myeloid Leukemia prevalence, Acute Myeloid Leukemia diagnosis rate, and Acute Myeloid Leukemia treatment rate for the period 2014 - 2020. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan.

1. Acute Myeloid Leukemia: Disease Definition

2. Global Acute Myeloid Leukemia Patient Flow

3. Acute Myeloid Leukemia Patient Flow in the US

4. Acute Myeloid Leukemia Patient Flow in Europe

5. Acute Myeloid Leukemia Patient Flow in Germany

6. Acute Myeloid Leukemia Patient Flow in France

7. Acute Myeloid Leukemia Patient Flow in Spain

8. Acute Myeloid Leukemia Patient Flow in Italy

9. Acute Myeloid Leukemia Patient Flow in UK

10. Acute Myeloid Leukemia Patient Flow in Japan

11. Appendix

For more information visit

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.